Cargando…

CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers

World Health Organization (WHO) data show that of the top 20 factors that threaten human life and health, cancer is at the forefront, and the therapeutic approaches for cancer consist of surgery, radiotherapy, chemotherapy and immunotherapy. For most highly metastatic and recurrent cancer, radiation...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xixi, Wu, Junying, Wang, Lingxia, Yang, Wei, Wang, Bo, Yang, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966018/
https://www.ncbi.nlm.nih.gov/pubmed/35372031
http://dx.doi.org/10.3389/fonc.2022.854678
_version_ 1784678564995530752
author Wu, Xixi
Wu, Junying
Wang, Lingxia
Yang, Wei
Wang, Bo
Yang, Huan
author_facet Wu, Xixi
Wu, Junying
Wang, Lingxia
Yang, Wei
Wang, Bo
Yang, Huan
author_sort Wu, Xixi
collection PubMed
description World Health Organization (WHO) data show that of the top 20 factors that threaten human life and health, cancer is at the forefront, and the therapeutic approaches for cancer consist of surgery, radiotherapy, chemotherapy and immunotherapy. For most highly metastatic and recurrent cancer, radiation therapy is an essential modality to mitigate tumor burden and improve patient survival. Despite the great accomplishments that have been made in clinical therapy, an inevitable challenge in effective treatment is radioresistance, the mechanisms of which have not yet been completely elucidated. In addition, radiosensitization methods based on molecular mechanisms and targets, and clinical applications are still inadequate. Evidence indicates that circular RNAs (circRNAs) are important components in altering tumor progression, and in influencing resistance and susceptibility to radiotherapy. This review summarizes the reasons for tumor radiotherapy resistance induced by circRNAs, and clarifies the molecular mechanisms and targets of action. Moreover, we determine the potential value of circRNAs as clinical indicators in radiotherapy, providing a theoretical basis for circRNAs-based strategies for cancer radiotherapy.
format Online
Article
Text
id pubmed-8966018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89660182022-03-31 CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers Wu, Xixi Wu, Junying Wang, Lingxia Yang, Wei Wang, Bo Yang, Huan Front Oncol Oncology World Health Organization (WHO) data show that of the top 20 factors that threaten human life and health, cancer is at the forefront, and the therapeutic approaches for cancer consist of surgery, radiotherapy, chemotherapy and immunotherapy. For most highly metastatic and recurrent cancer, radiation therapy is an essential modality to mitigate tumor burden and improve patient survival. Despite the great accomplishments that have been made in clinical therapy, an inevitable challenge in effective treatment is radioresistance, the mechanisms of which have not yet been completely elucidated. In addition, radiosensitization methods based on molecular mechanisms and targets, and clinical applications are still inadequate. Evidence indicates that circular RNAs (circRNAs) are important components in altering tumor progression, and in influencing resistance and susceptibility to radiotherapy. This review summarizes the reasons for tumor radiotherapy resistance induced by circRNAs, and clarifies the molecular mechanisms and targets of action. Moreover, we determine the potential value of circRNAs as clinical indicators in radiotherapy, providing a theoretical basis for circRNAs-based strategies for cancer radiotherapy. Frontiers Media S.A. 2022-03-16 /pmc/articles/PMC8966018/ /pubmed/35372031 http://dx.doi.org/10.3389/fonc.2022.854678 Text en Copyright © 2022 Wu, Wu, Wang, Yang, Wang and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wu, Xixi
Wu, Junying
Wang, Lingxia
Yang, Wei
Wang, Bo
Yang, Huan
CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers
title CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers
title_full CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers
title_fullStr CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers
title_full_unstemmed CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers
title_short CircRNAs in Malignant Tumor Radiation: The New Frontier as Radiotherapy Biomarkers
title_sort circrnas in malignant tumor radiation: the new frontier as radiotherapy biomarkers
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966018/
https://www.ncbi.nlm.nih.gov/pubmed/35372031
http://dx.doi.org/10.3389/fonc.2022.854678
work_keys_str_mv AT wuxixi circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers
AT wujunying circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers
AT wanglingxia circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers
AT yangwei circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers
AT wangbo circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers
AT yanghuan circrnasinmalignanttumorradiationthenewfrontierasradiotherapybiomarkers